JenaValve raises €19M second round funding

31 Mar 2010 | News

Funding

The medical device company JenaValve has raised €19 million from investors Gimv, Atlas Venture, Edmond de Rothschild Investment Partners, Neomed Management, VI Partners and Sunstone Capital, in a second round funding that will allow the company to further develop its aortic valve products and get them ready to market.   

JenaValve was founded in Munich in 2006, and raised €13.5 million its first round in 2007. It specialises in developing transcatheter aortic valves that can be implanted via the femoral vein, or an incision between two ribs. This makes them relatively easy to implant, in procedures that are minimally invasive. The technique is expected to be time- and cost-saving and to reduce the risk of complications, providing a suitable alternative to open heart surgery for elderly patients.

Patrick Van Beneden, Executive Vice-President Life Sciences of Gimv, who will hold an observer seat on JenaValve’s board of directors said, “JenaValve is Gimv’s second medtech investment in the last 12 months. The company has an experienced management team and the investment syndicate is very high level.”

Never miss an update from Science|Business:   Newsletter sign-up